The Gift for Life™ (TGFL)
Market Entry · Distribution Strategy · Advisory for Equity
April 2026 · Confidential & Proprietary
Prepared by the Pet Jet LLC Advisory Consortium — Pet Jet LLC · Scale Foundry · The Information Network (TIN) · Velocity Partners
Key Metrics at a Glance
$8.86B
Total Addressable Market
Global peptide + pet supplement markets (2025)
$3.2B
Serviceable Market (SAM)
Online, specialty retail & veterinary channels
818x
Digital Gap
vs. BodyBio benchmark — the #1 actionable lever
20%
Target Equity Stake
Advisory for Equity engagement model
Executive Summary
The Opportunity
Genostim's science is differentiated — 18 bioactive amino acids, 21 natural growth factors, and a patent-relevant pinocytosis absorption mechanism. The problem is infrastructure, marketing, and distribution.
The Proposition
The Pet Jet LLC Consortium proposes an Advisory for Equity engagement (15–20% stake) with co-investment support. At 3% SAM penetration (~$96M revenue) and a 3× multiple, the equity stake is projected at $43–58M by Year 5.
$3.1M
Y1 Target (0.1%)
$110M
Y5 Stretch (3%)
$43–58M
Equity Value Y5
Agenda
01
Company Overview
Genostim & The Gift for Life
02
Market Landscape
TAM, SAM, SOM
03
Competitive Position
Digital Gap Analysis
04
Revenue & Cash Flow
Scenarios & 36-Month Projections
05
Distribution & GTM
Channel Strategy & Roadmap
06
Advisory for Equity
Value Creation Model & Engagement Terms
Company Overview
Genostim Performance Labs operates two complementary brands — Genostim (human performance) and The Gift for Life / TGFL (companion animal wellness) — sharing a common science base.
The Science Platform
Core Complex
Isotide™/Hexatide™ — 18 amino acids, 21 natural growth factors including GF-1, GF-2, TGF-B, EGF, NGF, GHK-Cu + 10 more
Delivery Mechanism
Pinocytosis ("cell drinking") — peptides absorbed intact, bypassing digestive degradation
10 Benefit Pillars
Muscle recovery, cognitive function, immune support, joint health, skin/coat, energy, and more
Legal Status
GRAS designation — no FDA approval required for supplement claims; 20+ years R&D by Lauriston Crockett III
Dual-Brand Competitive Advantage
Household Penetration Strategy
The dual human/pet platform targets households with both pets and health-conscious adults — converting them to dual-brand subscribers.
The pet supplement channel provides a lower regulatory friction pathway to establish brand presence, build veterinary distribution, and generate cash flow while the human line scales.
Market Landscape
TAM · SAM · SOM — Market Opportunity
TAM — $8.86B
Global peptide ($4.1B, 18% CAGR) + US pet supplements ($4.76B, 10% CAGR)
SAM — $3.2B
Online DTC, specialty natural retail & veterinary channels (~36% of TAM)
SOM — $3.1M–$96M
0.1% penetration (Y1 base) to 3.0% penetration (Y5 stretch)
Market Tailwinds
Peptide Supplement Boom
Sub-market growing from $717M (2023) to $1.156B by 2033 (~7% CAGR). Broader functional supplement market exceeded $69.3B in 2023.
Pet Humanization
Pet supplements are one of the fastest-growing segments in pet care, driven by veterinary endorsement and premiumization of companion animal nutrition.
Secular Growth
Combined addressable opportunity projected to reach $11.3B by 2033 — a 27% increase from the current $8.86B baseline.
Competitive Position
The Digital Gap — 818× Deficit
818×
Gap to BodyBio benchmark
6,000×
Gap to category leaders
$275/mo
Genostim's current organic traffic value
The Opportunity
Competitors like Thorne and Garden of Life built $1M–$10M/month organic traffic over 5–10 years through content strategy, practitioner networks, and Amazon/retail presence.
Genostim's science matches or exceeds these brands at the molecular level. The opportunity is to build the commercial infrastructure that delivers that science to market at scale.

818× gap to BodyBio · 6,000× gap to category leaders
Competitive Digital Footprint
The Opportunity
Competitors like Thorne and Garden of Life built $1M–$10M/month organic traffic over 5–10 years through content strategy, practitioner networks, and Amazon/retail presence.
Genostim's science matches or exceeds these brands at the molecular level. The opportunity is to build the commercial infrastructure that delivers that science to market at scale.

818× gap to BodyBio · 6,000× gap to category leaders
Revenue Scenarios
Revenue by SAM Penetration Rate

Even at 0.1% SAM penetration, the business generates $3.2M annually. At 3% penetration, revenue reaches $96M — category leadership territory.
Revenue Scenario Summary
36-Month Cash Flow
Base Case P&L Projection
A conservative base case model projecting revenue growth from $0 to $16M+ over 36 months, driven by phased channel activation and compounding subscription revenue.
36-Month Cash Flow
Base Case P&L — 36-Month Detail
Key Assumptions
  • Initial investment: $500K deployed across inventory, e-commerce, and marketing
  • Breakeven projected at Q2 2027 (~Month 15)
  • Gross margin: 62% blended across channels
  • Autoship/subscription mix reaches 40% by Year 2, driving LTV expansion
  • No external debt assumed; model funded by operating cash flow post-breakeven

Base case assumes 0.5% SAM penetration by end of Year 2
Cash Flow Model Assumptions
Initial Investment
$500,000 — product inventory, e-commerce infrastructure, first 6 months of marketing
Gross Margin
55% — manufacturing, cold-chain packaging & fulfillment (premium DTC benchmark)
Marketing Spend
~35% of revenue in Year 1, declining to 18% by Year 3 as organic channels compound
Fixed OpEx
$80K/month — team, technology, overhead

Breakeven projected at Month 14–16 (cumulative cash basis) · Year 3 Revenue ~$38M
Distribution Strategy
Revenue by Channel — 3-Year Forecast
Channel Mix Strategy
  • DTC / E-Commerce leads in Year 1 — highest margin (70–75% GM), fastest to activate
  • Affiliate & influencer scales rapidly in Year 2 as content flywheel compounds
  • Veterinary & pet retail provides recurring B2B revenue and clinical credibility
  • Specialty retail and international unlock in Year 3 as brand equity matures

Conservative Base Case: 0.1% → 1.2% SAM Penetration · Year 1: $3.1M · Year 2: $11.8M · Year 3: $38M
Channel 1: DTC / E-Commerce
Highest-Margin Channel (~70–75% GM)
Priority platforms: brand website (Shopify), Amazon FBA, and Subscribe & Save / autoship programs.
Autoship is a critical metric — Chewy's autoship reached 82% of net sales by Q3 2024, demonstrating subscriber lock-in achievable in consumable wellness products.

Year 1 DTC Target: $1.2M
Channel 2: Affiliate & Influencer
High-Value Ecosystems
Key networks: ShareASale, Impact, CJ Affiliate. Benchmark commission: 15–20% recurring (Thorne standard).
Strategy targets Tier 2 micro-influencers (50K–500K followers) in sports recovery, anti-aging, and pet health — where authenticity conversion rates outperform celebrity endorsements.

Year 1 Target: $0.8M
Channel 3: Veterinary & Pet Retail
Highest AOV, Lowest CAC
Key veterinary distributors: MWI Animal Health, Patterson Veterinary, Covetrus.
Retail targets: Natural Grocers (no slotting fees), Whole Foods Market (premium positioning), Vitamin Shoppe (700+ stores).

Year 1 Vet + Pet Retail Target: $0.5M
Channels 4 & 5: Retail & International
Specialty Natural Retail
GNC (2,200 US stores) — requires slotting fees (~$150–500/SKU/store). Better early-stage options: independent health food stores, functional fitness gyms, CrossFit affiliates. Retail shelf entry is a Year 2 priority. Target: $1.5M.
International & Export
EU peptide supplement market, Canadian health food retail, and Southeast Asian nutraceutical markets. GRAS status simplifies import compliance. Preferred distributor model. Year 3 initiative. Target: $3.5M.
Market Growth
Addressable Market Growth (2022–2033)
Why This Market, Why Now
Combined addressable opportunity projected to reach $11.3B by 2033 — a 27% increase from the current $8.86B baseline.
  • US Peptide Supplements: ~18% CAGR (2023–2033)
  • US Pet Supplements: ~10% CAGR (2023–2033)
  • Genostim enters in 2026 — early enough to establish category authority, after the market has validated consumer demand

Combined market reaches $11.3B by 2033 · Genostim launch: 2026
Market Growth Data (2022–2033)
US Peptide Supplements: ~18% CAGR · US Pet Supplements: ~10% CAGR · Genostim Launch: 2026
Advisory for Equity
Value Creation Model
Equity Value Drivers
  • Revenue multiple: 3–6× applied to growing top line
  • Year 1 valuation: ~$5M (seed stage, pre-scale)
  • Year 3 valuation: ~$57M (post-breakeven, retail expansion)
  • Year 5 valuation: ~$240M (category leadership, M&A optionality)
  • 15–20% equity stake at entry = $36M–$48M value at Year 5

Advisory equity stake valued at $36M–$48M at Year 5 exit scenario
Equity Value Projections
Model Assumptions
Valuation modeled at a conservative 3× revenue multiple — appropriate for a growth-stage consumer wellness brand with differentiated science and strong recurring revenue.
At Y5 stretch revenue of $110M, company valuation reaches $330M.
15% Stake → $49.5M
20% Stake → $66M
Phased Revenue Build
Quarterly Revenue by Channel (Q1 2026 – Q2 2028)
Phased Ramp Logic
  • Q1–Q2 2026: DTC-only launch, affiliate seeding, vet pilot program
  • Q3–Q4 2026: Affiliate network live, vet distribution expanding
  • Q1–Q2 2027: Breakeven achieved, specialty retail onboarding begins
  • Q3 2027–Q2 2028: Full multi-channel activation, international pilots

Total quarterly run rate reaches $10.9M by Q2 2028 — annualized ~$43M
Quarterly Revenue Detail
Go-To-Market Roadmap
5-Phase GTM Roadmap
1
Foundation
Q1–Q2 2026 · Brand refresh, DTC launch, SEO foundation, affiliate seed · $0.3M
2
Traction
Q3–Q4 2026 · Influencer campaigns, vet pilot, Amazon FBA · $2.8M
3
Scale
2027 · National retail, autoship growth, content authority · $11.8M
4
Expansion
2028 · International markets, brand extensions, M&A · $30M
5
Leadership
2029–2030 · Category leadership, platform licensing, equity realization · $82–110M
Science-to-Market Activation
1
Month 1–3
Brand identity refresh, new e-commerce experience, clinical content library (10-pillar framework), affiliate program on ShareASale/Impact
2
Month 4–6
Amazon FBA launch, micro-influencer seed campaign (50 ambassadors), veterinary education portal, MWI distribution negotiation
3
Month 7–12
Autoship activation (40%+ subscriber target), paid media ($20–30K/month), first retail pilot (Natural Grocers, Vitamin Shoppe), PR/media strategy
Risk Factors
Risk Factors & Mitigants
FTC/FDA Claims Scrutiny — Medium
GRAS designation; structure/function claims with substantiation; legal review
Supply Chain Scale — Medium
Second-source contract manufacturer; 90-day inventory buffer policy
CAC Escalation — Medium
Channel diversification; organic SEO; affiliate/referral programs reduce CAC
Competitive Entry — Medium
Patent-relevant delivery mechanism; proprietary GF complex; first-mover advantage
Additional Risk Mitigants
Equity Dilution — Low
Phased equity tranches; co-investment syndicate; revenue-based financing
Pet Regulatory (NASC) — Low
NASC membership application; quality seal pursuit; veterinary advisory board
Amazon Policy Changes — Low
Multi-channel DTC strategy; email/SMS list ownership; brand registry protection
Engagement Terms
The Pet Jet LLC Consortium
Pet Jet LLC
Lead firm · Pet industry distribution, veterinary channel development, brand strategy
Scale Foundry
Operations, supply chain, fulfillment infrastructure, D2C platform architecture
The Information Network (TIN)
AI/technology, digital marketing automation, SEO/content strategy, analytics
Velocity Partners
Financial advisory, investor relations, co-investment syndication, CFO-level support
Engagement Terms Summary
Sources
Research References
Primary Sources
  • Crockett III, Lauriston. The Peptide Effect (7-volume series) — science foundation, pinocytosis mechanism, 10-pillar benefit framework
  • Genostim Performance Labs product documentation: genostim.com, thegiftforlife.com (April 2026)
  • Pet Jet LLC internal market research database and veterinary distribution network data
Market Data Sources
  • Grand View Research — Peptide Therapeutics Market, 2025
  • Allied Market Research — US Pet Supplement Market, 2023–2033
  • Euromonitor International — Global Nutraceuticals Market, 2024
  • Chewy Q3 2024 10-Q · GNC Holdings · Natural Grocers · ShareASale/Impact · MWI Animal Health · Patterson Veterinary · Covetrus Annual Report 2023

Competitive digital benchmarking sourced from market intelligence platforms and cross-referenced with publicly available domain authority and traffic estimation tools. Benchmarks include BodyBio, Thorne, Garden of Life, Vital Proteins, Ancient Nutrition, Life Extension, and Pure Encapsulations.
Why Now? The Inflection Point
Science Is Ready
20+ years of R&D, GRAS designation, defensible pinocytosis delivery mechanism — the product exists and is differentiated
Markets Are Growing
Both peptide (18% CAGR) and pet supplement (10% CAGR) markets are in confirmed secular growth with strong structural tailwinds
Gap Is Closeable
818× digital deficit is an infrastructure problem, not a product problem — exactly what a well-resourced advisory consortium is built to solve
Alignment Is Perfect
Advisory for Equity model aligns consortium incentives directly with Genostim's commercial success — no fees, only shared upside
The Gift for Life™
A scientifically differentiated platform. A $8.86B market. A consortium built to close the gap.
15–20% Equity
Advisory for Equity engagement
$49.5–66M
Projected equity value at Year 5
$330M
Company valuation at 3× Y5 revenue
© 2026 Pet Jet LLC Advisory Consortium · CONFIDENTIAL · Not for distribution without written consent